Our Business

Introducing Our Business Fields; from Health, Pre-symptomatic State to Treatment

Business overview

As of March 2023, our core areas of business are OTC drugs (over-the-counter drugs) and skincare. In line with the ROHTO Group Comprehensive Management Vision 2030, the business domain vision 2030 aims to grow the functional food business as the third pillar of our core domain. We are also focusing on medical ophthalmology, regenerative medicine, and contract development and manufacturing (CDMO) as business expansion areas.

Furthermore, we believe that connecting businesses and creating new synergies is also one of the actions to realize this. We continue to take on challenges in various businesses, including primary industries such as agriculture and food businesses such as restaurants.

Currently, we are expanding our network in more than 110 countries around the world. By connecting people around the world with their health, we aim to deliver well-being to people around the world and realize a sustainable society where people can live long, healthy and happy lives.

image of our business expansion toword for 2030
  • OTC drugs (over-the-counter drugs)

    We deliver safe, secure, and functional products based on research that only a pharmaceutical company can, while staying close to the concerns of a wide range of customers.

  • Skin care

    We deliver functional products through evidence-based research and development that pursues safety, efficacy, and mechanisms by applying basic research and core technologies unique to a pharmaceutical company and knowledge of regenerative medicine research.

  • Functional food/Food

    Pre-symptomatic disease and prevention at the stage of going from health to illness. Furthermore, we pay attention to meal to make body. We collaborate with group companies to deliver products that utilize the materials owned by each company.

  • Ophthalmology Area

    We have built up expertise in OTC medicines manufacturing over many decades. We leverage the capabilities to develop ethical ophthalmologic medicines and medical devices in collaboration with Group companies and partners in order to deliver eyecare solutions.

  • Regenerative Medicines

    We are pursuing research and development of regenerative medicine products using stem cells in order to meet unmet medical needs that still lack satisfactory treatment methods.

  • Contract Development and Manufacturing Organization (CDMO)

    We are advancing our current contract manufacturing (CMO) business by making full use of the know-how and technologies we have cultivated in regenerative medicine-related businesses and other areas. We are promoting a development and manufacturing contract (CDMO) business that provides one-stop development and manufacturing of products in the biotechnology field that leverages our own development capabilities.

Global expansion

We deliver our products to more than 110 countries around the world. We will contribute to well-being through our own approaches, even in situations that differ from country to country, such as climate, regulations, and logistics, by staying close to local cultures and customs.